Autoantibodies in Atrial Fibrillation: Actors, Biomarkers or Bystanders? How Far Have We Come?

Publisher： Karger

E-ISSN： 1421-9751|112|3|178-179

ISSN： 0008-6312

Source： Cardiology, Vol.112, Iss.3, 2008-07, pp. : 178-179

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

The International AIDS Conferences from Vancouver to Bangkok: How far have we come in eight years?

By Mukherjee Joia S.  

Revista Panamericana de Salud Pública/Pan American Journal of Public Health, Vol. 16, Iss. 2, 2004-08 ,pp. : 75-77

Pan American Health Organization (PAHO)

Access to resources Recommend Favorite

Emerging engineered magnetic nanoparticulate probes for molecular MRI of atherosclerosis: how far have we come?

By Kanwar Rupinder K   Chaudhary Rajneesh   Tsuzuki Takuya   Kanwar Jagat R  

Nanomedicine, Vol. 7, Iss. 6, 2012-06 ,pp. : 899-916

Future Medicine

Access to resources Recommend Favorite

Chemical Pleurodesis for Malignant Pleural Effusion: How Far Have We Come in 80 Years?

By  

Respiration, Vol. 90, Iss. 5, 2015-0 ,pp. : 355-356

Karger

Access to resources Recommend Favorite

Geriatric Oncology: How Far Have We Gone and What Are the Next Steps?

By  

Oncology, Vol. 77, Iss. 3-4, 2009-07 ,pp. : 147-156

Karger

Access to resources Recommend Favorite

Circulating cardiac biomarkers and postoperative atrial fibrillation in the OPERA trial

By  

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (ELECTRONIC), Vol. 45, Iss. 2, 2015-02 ,pp. : 170-178

John Wiley & Sons Inc

Access to resources Recommend Favorite